<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005982</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02344</org_study_id>
    <secondary_id>ID99-213</secondary_id>
    <secondary_id>CDR0000067970</secondary_id>
    <nct_id>NCT00005982</nct_id>
  </id_info>
  <brief_title>506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma</brief_title>
  <official_title>Phase II Study of 506U78 (NSC #686673) in Patients With Previously Treated Cutaneous T-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop&#xD;
      growing or die. Phase II trial to study the effectiveness of 506U78 in treating patients who&#xD;
      have recurrent or refractory cutaneous T-cell lymphoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the response rate, failure-free survival, and progression-free survival of&#xD;
      patients with recurrent or refractory cutaneous T-cell lymphoma treated with 506U78.&#xD;
&#xD;
      II. Determine the toxicity of this drug in these patients. III. Study the pharmacokinetics of&#xD;
      this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment continues every 28&#xD;
      days for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 6 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-35 patients will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administratively complete.&#xD;
  </why_stopped>
  <start_date>April 2000</start_date>
  <primary_completion_date type="Actual">July 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (RR) defined as CR + PR rates</measure>
    <time_frame>Up to 4 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Mycosis Fungoides/Sezary Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment (nelarabine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment continues every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nelarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (nelarabine)</arm_group_label>
    <other_name>506U78</other_name>
    <other_name>Arranon</other_name>
    <other_name>GW506U78</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (nelarabine)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed relapsed or refractory cutaneous T-cell lymphoma&#xD;
&#xD;
               -  Large cell transformation of cutaneous T-cell lymphoma allowed&#xD;
&#xD;
          -  No active CNS disease&#xD;
&#xD;
          -  Performance status - Zubrod 0-2&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm^3*&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3*&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGPT no greater than 2.5 times ULN&#xD;
&#xD;
          -  Creatinine clearance greater than 50 mL/min&#xD;
&#xD;
          -  No history of symptomatic cardiac dysfunction&#xD;
&#xD;
          -  No history of pericardial effusion&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No grade 2 or greater sensory or motor neuropathy&#xD;
&#xD;
          -  No history of seizures&#xD;
&#xD;
          -  No other malignancy within the past 5 years except curatively treated basal cell&#xD;
             carcinoma of the skin of carcinoma in situ of the cervix&#xD;
&#xD;
          -  No medical, psychiatric, or social condition that would preclude study&#xD;
&#xD;
          -  No other concurrent serious illness or active infection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior stem cell or bone marrow transplantation (BMT)&#xD;
&#xD;
          -  No more than 1 prior immunotherapy regimen&#xD;
&#xD;
          -  No more than 3 prior systemic regimens with denileukin diftitox&#xD;
&#xD;
          -  At least 3 weeks since prior biologic therapy&#xD;
&#xD;
          -  No concurrent BMT&#xD;
&#xD;
          -  No prior 506U78&#xD;
&#xD;
          -  No more than 3 prior systemic chemotherapy regimens comprising any of the following:&#xD;
&#xD;
               -  Oral methotrexate&#xD;
&#xD;
               -  Topical mechlorethamine&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior anticancer endocrine therapy&#xD;
&#xD;
          -  No concurrent topical or systemic steroids&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
          -  No more than 3 prior systemic regimens comprising any of the following:&#xD;
&#xD;
               -  Total skin electron beam therapy&#xD;
&#xD;
               -  Spot radiotherapy&#xD;
&#xD;
          -  No more than 3 prior systemic regimens comprising any of the following:&#xD;
&#xD;
               -  Oral retinoids&#xD;
&#xD;
               -  Ultraviolet therapy (PUVA)&#xD;
&#xD;
          -  At least 3 weeks since prior anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andre Goy</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Sezary Syndrome</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

